Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Immutep Ltd ( (AU:IMM) ) is now available.
Immutep Limited has received a notice from Nasdaq that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00 per share, after trading below that threshold for 30 consecutive business days through 24 April 2026. The notification does not immediately affect the listing or trading of its ADSs on Nasdaq, and the company’s ordinary shares continue to trade as normal on the ASX.
Nasdaq has granted Immutep an initial 180-day compliance period, ending 26 October 2026, during which the company must lift its ADS closing bid price to at least US$1.00 for a minimum of ten consecutive business days to regain compliance. Immutep says it will closely monitor its share price and consider available options to restore compliance, with the outcome potentially affecting its U.S. market presence and investor perception, while committing to keep the market informed of any material developments.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in LAG-3 (Lymphocyte Activation Gene-3) biology and is advancing a diversified portfolio of LAG-3-based therapeutics designed to either stimulate or suppress the immune system, targeting patients with high unmet medical need and aiming to create value for shareholders.
Average Trading Volume: 41,079,770
Technical Sentiment Signal: Sell
Current Market Cap: A$104.6M
See more data about IMM stock on TipRanks’ Stock Analysis page.